Cargando…

Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries

INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitropoulos, Dionysios, Chlosta, Piotr, Häggman, Michael, Ström, Torbjorn, Markussis, Vyron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318023/
https://www.ncbi.nlm.nih.gov/pubmed/34336233
http://dx.doi.org/10.5173/ceju.2021.0343.R1
_version_ 1783730169566986240
author Mitropoulos, Dionysios
Chlosta, Piotr
Häggman, Michael
Ström, Torbjorn
Markussis, Vyron
author_facet Mitropoulos, Dionysios
Chlosta, Piotr
Häggman, Michael
Ström, Torbjorn
Markussis, Vyron
author_sort Mitropoulos, Dionysios
collection PubMed
description INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of patients with PC was conducted in eight European countries between February and May 2018. Survey recipients were selected from a private database of healthcare providers. RESULTS: Overall, 375 physicians completed the survey (response rate, 58%). Participants were urologists (71.2%) or medical oncologists (28.8%), with a mean practice duration of 19.9 years and with university hospital or cancer center (41.6%), non-teaching hospital (38.4%) or private-sector clinic (20.0%) affiliations. Median proportions of physicians considering ADT as monotherapy to treat patients with PC in different risk groups varied between countries, but overall were: high/very high-risk, 60%; intermediate-risk, 30%; low-risk, 7.5%. The use of ADT monotherapy in the different risk groups also varied by medical specialty and type of affiliation. Proportions of participants applying different target thresholds for testosterone (T) levels also varied by country, but overall were: <50 ng/dL, 29.9%; <32 ng/dL, 4.8%; <20 ng/dL, 54.3%; castration but no specific target, 11%. More than half of participants (58.7%) determined target T levels only when prostate-specific antigen level was increased. CONCLUSIONS: Our multinational survey provides evidence that PC management varies across European countries and with clinical context, and frequently diverges from European Association of Urology (EAU) – European Society for Radiotherapy and Oncology (ESTRO) – European Society of Urogenital Radiology (ESUR) – International Society of Geriatric Oncology (SIOG) guidelines. Strategies for effective implementation of evidence-based recommendations in clinical practice may be needed to optimize patient outcomes.
format Online
Article
Text
id pubmed-8318023
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Polish Urological Association
record_format MEDLINE/PubMed
spelling pubmed-83180232021-07-30 Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries Mitropoulos, Dionysios Chlosta, Piotr Häggman, Michael Ström, Torbjorn Markussis, Vyron Cent European J Urol Original Paper INTRODUCTION: The aim of this study was to investigate the attitudes towards use of androgen deprivation therapy (ADT) as monotherapy for localized or locally advanced prostate cancer (PC). MATERIAL AND METHODS: A survey using a 28-item, structured, quantitative questionnaire about the management of patients with PC was conducted in eight European countries between February and May 2018. Survey recipients were selected from a private database of healthcare providers. RESULTS: Overall, 375 physicians completed the survey (response rate, 58%). Participants were urologists (71.2%) or medical oncologists (28.8%), with a mean practice duration of 19.9 years and with university hospital or cancer center (41.6%), non-teaching hospital (38.4%) or private-sector clinic (20.0%) affiliations. Median proportions of physicians considering ADT as monotherapy to treat patients with PC in different risk groups varied between countries, but overall were: high/very high-risk, 60%; intermediate-risk, 30%; low-risk, 7.5%. The use of ADT monotherapy in the different risk groups also varied by medical specialty and type of affiliation. Proportions of participants applying different target thresholds for testosterone (T) levels also varied by country, but overall were: <50 ng/dL, 29.9%; <32 ng/dL, 4.8%; <20 ng/dL, 54.3%; castration but no specific target, 11%. More than half of participants (58.7%) determined target T levels only when prostate-specific antigen level was increased. CONCLUSIONS: Our multinational survey provides evidence that PC management varies across European countries and with clinical context, and frequently diverges from European Association of Urology (EAU) – European Society for Radiotherapy and Oncology (ESTRO) – European Society of Urogenital Radiology (ESUR) – International Society of Geriatric Oncology (SIOG) guidelines. Strategies for effective implementation of evidence-based recommendations in clinical practice may be needed to optimize patient outcomes. Polish Urological Association 2021-03-26 2021 /pmc/articles/PMC8318023/ /pubmed/34336233 http://dx.doi.org/10.5173/ceju.2021.0343.R1 Text en Copyright by Polish Urological Association https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Mitropoulos, Dionysios
Chlosta, Piotr
Häggman, Michael
Ström, Torbjorn
Markussis, Vyron
Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title_full Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title_fullStr Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title_full_unstemmed Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title_short Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries
title_sort androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight european countries
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318023/
https://www.ncbi.nlm.nih.gov/pubmed/34336233
http://dx.doi.org/10.5173/ceju.2021.0343.R1
work_keys_str_mv AT mitropoulosdionysios androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries
AT chlostapiotr androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries
AT haggmanmichael androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries
AT stromtorbjorn androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries
AT markussisvyron androgendeprivationmonotherapyusageinnonmetastaticprostatecancerresultsfromeighteuropeancountries